Kornimate/medical-research-clean huggingface dataset:
diverse training programs and sarcopenia in postmenopausal women

Conditions: Sarcopenia

Summary: this study explored preventive measures for sarcopenia in apparently healthy postmenopausal women. the investigators implemented a short nordic walking intervention, bungy pumo exercises and strength training, and conducted a 3-month training program as an intervention method. the subjects divided into the nw (nordic walking) test group, the st (strength training) test group, bp (bungy pump exercises) test group and the control group, which engaged in regular daily activities without any additional physical exercise. the collected experimental data then processed and analyzed to objectively assess the benefits and limitations of different interventions.

the tests were conducted twice (before and after the training period). each test lasted two days and will be preceded by a 7-day measurement of physical activity using sport testers. on the first day, blood tests, microbiota, body composition and a preliminary analysis of diet diaries were performed. on the second day, physical fitness tests were carried out in the physical exercise laboratory of the awfis in gdańsk. biological material (blood serum and feces) was frozen for testing by the project contractors in the laboratory of genetics in sports of the awfis. the subjects were required to keep a diet diary in which they recorded meals during the 3 days preceding the blood and intestinal microbiota test.

Eligibility criteria:
inclusion criteria: postmenopausal women over 60 years old (i.e. more than 12 months since their last menstrual cycle). there were no contraindications to exercise after case reports and initial diagnosis. informed consent must be signed, agreeing to participate in research and physical exercise programs. exclusion criteria: uncontrolled high blood pressure. coronary artery disease. rheumatoid arthritis. type 2 diabetes. respiratory diseases and lung diseases. are taking or have used antibiotics and/or antifungal therapy in the past 4 weeks. unwillingness to stick to a prescribed schedule.

Keywords: sarcopenia postmenopausal women nordic walking strength training bungy pump exercises
identification of vocal biomarkers to monitor the health of people with a chronic disease

Conditions: Chronic Disease

Summary: the colive voice research project aims to identify vocal biomarkers of severe conditions and frequent health symptoms. the project is based on digital technologies and statistical algorithms. this is an international anonymous survey where vocal recordings are collected simultaneously with large validated clinical and epidemiological data, in the context of various chronic diseases or frequent health symptoms in the general population.

with the objective of using vocal biomarkers for diagnosis, risk prediction/stratification and remote monitoring of various clinical outcomes and symptoms, there is a major need to develop surveys where audio data and clinical, epidemiological and patient-reported outcomes data are collected simultaneously. the objectives of colive voice are: * to launch an international anonymized survey where vocal recordings are associated with large validated clinical and epidemiological data, in the context of various chronic diseases or frequent health symptoms in the general population * to extract audio features and train supervised machine learning models to identify key candidate vocal biomarkers of the aforementioned chronic conditions or related symptoms. participants will be recruited online and will complete the survey using a web application. they will first answer a detailed questionnaire on their health status and then do 5 different voice records: 1. read a 30 sec prespecified text (from the human rights declaration), 2. sustain voicing the vowel /aaaaaa/ as long and as steady as they can at a comfortable loudness 3. cough 3 times 4. breath in and out deeply 3 times 5. count from 1 to 20 at a normal speed vocal records will be pre-processed and converted into features, meaning the most dominating and discriminating characteristics of a vocal signal. following the selection of features, machine or deep learning algorithms will be trained to automatically predict or classify the clinical, medical or epidemiological outcomes of interest, from vocal features alone or in combination with other health-related data.

Eligibility criteria:
inclusion criteria: * adolescents and adults \> 15 years * with or without health conditions * from all countries exclusion criteria: * children \< 15 years

Keywords: vocal biomarker digital biomarker digital health artificial intelligence telemonitoring medical devices precision health digital biomarker
therapeutic cancer vaccine (ast-301, pngvl3-hicd) in patients with breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate the efficacy and safety of an adjuvant treatment of therapeutic cancer vaccine (ast-301, pngvl3-hicd) in patients with her2-low expression (ihc 1+ or 2+ and ish-) and hormone receptor-negative(er-, pr-) breast cancer with residual disease after neoadjuvant treatment. patients will be randomized 1:1 to either the experimental arm (combination of ast-301/rhugm csf and standard adjuvant therapy) or the control arm (combination of placebo/rhugm csf and standard adjuvant therapy). standard adjuvant chemotherapy will be pembrolizumab or capecitabine. adjuvant therapy will be administered in compliance with the nccn guideline for breast cancer (version 8, 2021), and ip (ast-301) will be administered 3 times every 3 weeks in the adjuvant treatment period, with a booster administered at 24 weeks (±7 days) post the third dose of ip administration. survival follow up will be performed to determine invasive disease free survival(idfs).

not provided

Eligibility criteria:
key inclusion criteria: * has a residual invasive cancer in the breast(non-pcr) after neoadjuvant treatment * has stage i, ii, or iii disease prior to surgery per american joint committee on cancer (ajcc) * her 2 1+ by ihc or her2 2+by ihc without gene amplification by ish, as defined by american society of clinical oncology (asco)/college of american pathologists (cap) guidelines. * hormone receptor (er and pr) negative by asco/cap guidelines * eastern cooperative oncology group (ecog) performance status of 0 or 1 * demonstrates adequate organ function. key exclusion criteria: * has a history of hypersensitivity or other contraindications to rhgm-csf * has a history of invasive malignancy ≤5 years prior to first administration of investigational drug except for adequately treated non-melanoma skin cancer or carcinoma in situ. * is on immune suppression therapy or has a history of immune suppression therapy ≤4 weeks prior to the first administration of investigational drugs * has a history of autoimmune disease or inflammatory disease * has active infection including tuberculosis, hepatitis b, hepatitis c or human immunodeficiency virus (hiv) infection * is pregnant or breastfeeding or expecting to conceive children

Keywords: her 2 low (1+ or 2+ and non-amplified by fish)
electrophysiological effects of guanfacine extended release in attention deficit hyperactivity disorder (adhd)

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: all subjects with the study will be children (age 6-12) with attention deficit hyperactivity disorder (adhd). after baseline assessment confirms the presence of adhd, children will have an event related potential (erp) (a type of electroencephalogram \[eeg\]) study. after the baseline eeg, children will be randomized to either placebo or gxr for a 4-week, parallel groups trial. during this trial, dosing will be flexibly adjusted according to patient response or presence of side effects. the dosage will range from 1-4 mg. at the end of the four week trial, a follow up erp study will be obtained.

all subjects with the study will be children (age 6-12) with attention deficit hyperactivity disorder (adhd). after baseline assessment confirms the presence of adhd, children will have an event related potential (erp) (a type of electroencephalogram \[eeg\]) study. after the baseline eeg, children will be randomized to either placebo or gxr for a 4-week, parallel groups trial. during this trial, dosing will be flexibly adjusted according to patient response or presence of side effects. the dosage will range from 1-4 mg. at the end of the four week trial, a follow up erp study will be obtained. our hypotheses are: a) gxr will be superior to placebo at reducing symptoms of adhd as measured by standardized clinical diagnostic tools by week 3 of treatment. b) compared to placebo and pretreatment measures, gxr at week 4 of treatment will increase the amplitude of the right frontal n200 and frontal-central p300, and such changes will correlate with clinical response.

Eligibility criteria:
inclusion criteria: * children aged 6-12 years * meet criteria for attention deficit hyperactivity disorder exclusion criteria: * do not meet criteria for major depression, bipolar, autism * talking any psychotropic medication for a condition other than adhd * history of epilepsy, severe head injury or loss of consciousness * history of intolerance to guanfacine

Keywords: attention deficit disorder with hyperactivity guanfacine event related potentials
rca for crrt in hyperlactatemia patient with increased bleeding risk

Conditions: Continuous Renal Replacement Therapy; Hyperlactatemia; Bleeding

Summary: the purpose of this single center, randomized, control, open-labeled study is to evaluate the effect and safety of rca versus no anticoagulation for crrt in hyperlactatemia patients with increased bleeding risk.

for continuous renal replacement therapy (crrt) patients with shock and muscle hypoperfusion, which characterised by tissue hypoxia and hyperlactatemia, the kidney disease improving global outcomes (kidigo) guideline recommended no use of regional citrate anticoagulation (rca) considering the potential increased citrate accumulation (ca) risk. in the condition of increased bleeding, no-anticoagulation was recommended for these patients. however, crrt processed without anticoagulation was proved to be associated with shorter filter lifespan. therefore, the purpose of this single center, randomized, control, open-labeled study is to evaluate the safety and efficacy of rca versus no-anticoagulation for crrt in hyperlactatemia patients with increased bleeding risk.

Eligibility criteria:
inclusion criteria: * age≥16 years * hyperlactatemia (lactic acid or serum lactate level \> 2 mmol/l) * required crrt * increased bleeding risk: plt \ 60 s, inr \> 1.5, bleeding or active bleeding within 7 days, recent trauma or surgery (especially head trauma and neurosurgery), recent stroke, intracranial venous malformation or aneurysm, retinal hemorrhage, uncontrolled hypertension, and epidural catheter implantation. exclusion criteria: * drugs (biguanide, linezolid, cyanide, etc.) and congenital metabolic disorders (glucose-6 phosphatase and 1,6 phosphofructosase deficiency) and mitochondrial damage caused hyperlactatemia. * receiving systemic anticoagulant treatment (heparin/lmol/warfarin/aspirin, etc.) within 24 hours. * critical patients with lactic acid ≥15mmol\\l (with a mortality of 100%) were excluded * patients with aptt \> 100s were excluded (retrospective data suggested that this type of patients received crrt treatment should last for more than 24 hours) * patients who are pregnant or during lactation * severe liver failure: child-pugh score \>10 (chronic severe liver failure), meld score \> 30 (acute severe liver failure), total bilirubin \>51 mol/l * patients with internal fistula were treated with crrt * unable to cooperate with treatment due to mental problems (such as depression and mental illness) * crrt with arteriovenous fistula, or the prescribed treatment time \< 12 hours
lafiya hiv self-testing study protocol

Conditions: HIV Prevention and Care

Summary: the study aims to address low testing and related issues such as stigma, low-risk perception, and concerns about confidentiality affecting testing. to overcome these challenges, the study proposes to adapt the many men many voices (3mv) into a modified version called lafiya to tackle intersectional stigma and improve hivst among young sexual minority men in ghana.


Eligibility criteria:
inclusion criteria: * ysmm: to be eligible to participate in the interview, the person must be between 18 to 25 years old, have no experience using unassisted hivst kits, do not know their hiv status or tested negative, currently identifies as cis-gender man, and have had sex with another man within six months before engaging with the recruitment team and must reside within a slum community in the greater accra metropolitan area. * providers: to be eligible to participate in the interview, the person must have experience providing sexual health services such as hiv testing, counseling, and linkage to prevention and care services for at least one year. must reside within the greater accra metropolitan area and have worked with ysmm on hiv prevention and care. exclusion criteria: * ysmm: those who fall under 18 years or above 25 years will be excluded from the study. ysmm who have experience with unassisted hivst kits, know their hiv status, or tested positive for hiv will be excluded from the study. ysmm who do not identify as cis-gender man and have not had sex with another man within six months before engaging with the recruitment team will be excluded from the study. ysmm who do not reside within a slum community in the greater accra metropolitan area will be excluded from the study. * providers: persons who do not have experience providing services such as hiv testing, counseling, and linkage to prevention and care services for at least one year will be excluded from the study. providers not residing within the greater accra metropolitan area and have not worked with ysmm on hiv prevention and care will be excluded.
randomized controlled trial comparing irrisept versus normal saline for wound irrigation after posterior spine surgery

Conditions: Lumbar Spine Degeneration; Cervical Spine Degeneration

Summary: to compare post-operative wound complications in patients randomized to normal saline versus irrisept solution and any other adverse reactions from the solution.

wound complications represent a significant risk factor in spinal surgery, particularly in complex multilevel procedures. surgical site infections (ssi) are the most common health care-associated infection, accounting for 31% of all hospitalized patients with a health care-associated infection. the reported incidence of ssis following spine surgery ranges from 0.2% to 18.8%. in one study, each episode of wound infection following spine procedure contributed to a mean increase in the cost of care by $4,067 compared to a non-complicated case. the bacteria can adhere to the implants and tissues to create biofilm made by polysaccharide matrix which makes it challenging to clear the infection. different irrigation techniques and solutions have been utilized to help limit post-operative wound complications. no studies have compared irrisept solution to normal saline to see if there is a difference in wound complications for posterior spine surgeries.

Eligibility criteria:
inclusion criteria: * presenting to the university of missouri hospital system - including the university of missouri hospital and missouri orthopaedic institute - with a need for isolated open posterior spine procedures using a posterior open approach. * failed conservative treatment - rest, anti-inflammatory medications, physical therapy * \>18 years old and able to provide informed consent exclusion criteria: * ongoing or suspected infection * revisions of failed back surgeries * documented allergy to chg or chg products * pregnancy - qualitative beta human chorionic gonadotropin (hcg) testing will be performed prior to enrollment * prisoners or wards of the state * unable to consent to research study
non-pharmacological methods for the control of anxiety and pain during outpatient hysteroscopy

Conditions: Pain, Postoperative

Summary: the administration of pharmacological and non-pharmacological aids during in-office hysteroscopic surgery is often used to both relieve the patient from discomfort and facilitate the operator in performing the procedure. the investigators aim to test the hypothesis that watching a video clip or listening to music would act as non-pharmacological relief for reducing anxiety and pain during in-office hysteroscopy.


Eligibility criteria:
inclusion criteria: * premenopausal and postmenopausal women * indication for in-office operative hysteroscopy exclusion criteria: * denied consent * use of analgesic drugs before the procedure
surgical trial in lobar intracerebral haemorrhage

Conditions: Intracerebral Haemorrhage

Summary: to establish whether a policy of earlier surgical evacuation of the haematoma in selected patients with spontaneous lobar ich will improve outcome compared to a policy of initial conservative treatment. the trial will also help to better define the indications for early surgery. this will overcome two of the criticisms of stich (timing was too late and sometimes location was too deep). the subgroup identified in stich is clinically sensible and the hypothesis identified for stich ii is in line with current neurosurgical opinion.

stich ii is an international multicentre randomised parallel group trial comparing early craniotomy to evacuate the haematoma with initial conservative treatment, following spontaneous superficial intracerebral haemorrhage affecting the lobar region only. only patients for whom the treating neurosurgeon is in equipoise about the benefits of early craniotomy compared to initial conservative treatment are eligible for the trial. outcome is measured at six months via a postal questionnaire including the glasgow outcome scale, modified rankin scale, euroqol and barthel. six hundred patients will be recruited to the trial over thirty months. follow-up will take six months with analysis and reporting taking one year.

Eligibility criteria:
inclusion criteria: * evidence of a spontaneous lobar ich on ct scan (1 cm or less from the cortex surface of the brain) * patient within 48 hours of ictus * best motor score on the gcs of 5 or 6 and best eye score on the gcs of 2 or more. * volume of haematoma between 10 and 100ml \[calculated using (a x b x c)/2 method\] exclusion criteria: * clear evidence that the haemorrhage is due to an aneurysm or angiographically proven arteriovenous malformation. * intraventricular haemorrhage of any sort * ich secondary to tumour or trauma. * basal ganglia, thalamic, cerebellar or brainstem haemorrhage or extension of a lobar haemorrhage into any of these regions. * severe pre-existing physical or mental disability or severe co-morbidity which might interfere with assessment of outcome. * if surgery cannot be performed within 12 hours. * if the haematological effects of any previous anticoagulants are not completely reversed.

Keywords: intracerebral haemorrhage
transconjunctival needling revision versus medical treatment

Conditions: Primary Open Angle Glaucoma

Summary: when the glaucoma filtering surgery failures (intraocular pressure rises again), the options is start to use the hypotensive eye drops again (medical treatment). however, in some cases (encapsulated blebs), there is a simple surgical revision that can revival the primary failure surgery. it calls transconjunctival needling revision. in this study, the investigators compare the efficacy of this revision versus medical treatment in 12-month follow up in eyes with encapsulated blebs.

to compare the efficacy of transconjunctival needling revision (tnr) with 5-fluorouracil versus medical treatment (mt) in glaucomatous eyes with uncontrolled intraocular pressure (iop) due to encapsulated bleb after trabeculectomy prospective, randomized, interventional study. a total of forty eyes of 39 patients with elevated iop and encapsulated bleb diagnosed at maximum 5 months after primary trabeculectomy with mitomycin c were included. the eyes were randomized to either tnr with 5-fluorouracil or mt (hypotensive eyedrops). a maximum of two tnr per patient was allowed in the needling arm. all eyes were followed up for 12 months. success of treatment was defined as iop ≤ 18mmhg and 20% reduction from baseline at last follow up.

Eligibility criteria:
inclusion criteria: * eyes with encapsulated blebs developed in 5 months or less following primary glaucoma filtering surgery (trabeculectomy) and intraocular pressure \>= 20mmhg exclusion criteria: * previous other ocular surgery

Keywords: encapsulated blebs trabeculectomy failure glaucoma
sbrt compared with imrt concurrently with chemotherapy in treating patients with ls-sclc

Conditions: Small Cell Lung Cancer

Summary: as stereotactic radiotherapy (sbrt) has been widely used in clinical practice at present, the aim of this study is to evaluate the efficacy and safety of stereotactic body radiation therapy compared with intensity modulated radiation therapy (imrt) concurrently with ep regimen(cisplatin plus etoposide) in treating patients with limited-stage small cell lung cancer


Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis of sclc * limited-stage disease is defined as disease confined to the ipsilateral hemithorax, which can be safely encompassed within a radiation field * no prior chemotherapy, or radiotherapy * performance status of 0, 1, 2 on the ecog criteria. * at least one unidimensional measurable lesion meeting response evaluation criteria in solid tumors (recist. 2000). * adequate hematologic (neutrophil count \>= 1,500/ul, platelets \>= 100,000/ul), hepatic (transaminase =\< upper normal limit(unl)x2.5, bilirubin level =\< unlx1.5), and renal (creatinine =\< unl) function * if female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device \[iud\], birth control pills, or barrier device) during and for 3 months after trial. if male, use of an approved contraceptive method during the study and 3 months afterwards. females with childbearing potential must have a urine negative hcg test within 7 days prior to the study enrollment. exclusion criteria: * non small cell lung cancer and carcinoid * supraclavicular lymphadenopathy * inability to comply with protocol or study procedures. * moderate and severe ventilation dysfunction * medically uncontrolled serious heart, lung, neurological, psychological, metabolic disease * second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * pregnant or breast-feeding. * enrollment in other study within 30 days

Keywords: limited-stage small cell lung cancer stereotactic body radiation therapy intensity modulated radiation therapy radiation chemotherapy